Latest News

ACTRIMS Forum 2022 – Update on anti-CD20s and vaccine response

 

SPECIAL REPORT

Several studies presented at the ACTRIMS Forum 2022 provided some additional details on the COVID-19 vaccine response among MS patients treated with anti-CD20 therapies. The data suggest that vaccine response may differ somewhat among anti-CD20 agents, which may be related to the depth and/or duration of B cell suppression, the timing of vaccination and patient factors such as age. Read More